CAR-T Followed by Bispecific Antibodies

Recruiting

18-99 years

All

Phase 2

40 participants needed

1 Location

Brief description of study

The research study is being conducted to test the safety and effectiveness of the experimental drug mosunetuzumab or obinutuzumab and glofitamab (Cohort 2) when given after CAR (genetically modified) T cells. The study is for patients who have already received a CAR T-cell infusion. Some patients who join the study will receive mosunetuzumab, other patients later in the study may receive a different experimental drug (glofitamab, in combination with obinutuzumab).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions:
Large B-cell Lymphoma
Age: Between 18 Years - 99 Years
Gender: All

Male or Female, Age 18 or older Life expectancy of at least 12 weeks, History of relapsed or refractory DLBCL, HGBCL, PMBCL or tFL who have relapsed after or failed to respond to at least two prior standard systemic treatment regimens

Updated on 09 Mar 2024. Study ID: 844799

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).